Amaru J. Sanchez provides substantive legal and strategic advice to FDA clients in matters concerning regulatory compliance, enforcement issues, and public policy. Amaru’s advice spans a variety of FDA regulated products including foods and food additives, medical devices, and software as a medical device, as well as prescription and non-prescription drugs. As part of his administrative law practice, Amaru also assists with evaluations and filings for clearance before the Committee on Foreign Investment in the United States (CFIUS), representing both foreign buyers/investors and domestic sellers of US businesses, including on transactions affecting the life sciences industry.
Prior to joining Morgan Lewis, Amaru served as a project manager/senior analyst at the National Quality Forum (NQF) Measure Applications Partnership, established to provide multi-stakeholder input to the Department of Health and Human Services on the selection of performance measures for public reporting and payment reform programs. He also served as the senior health policy research analyst and acting committee director for the bicameral Public Health Committee at the Massachusetts Legislature before he worked at NQF. At the legislature, Amaru influenced the passage of several novel public health and healthcare related laws and drafted legislative proposals relative to medical debt, chronic disease management, health disparities, and health care transparency.
Catholic University of America, Columbus School of Law, 2017, J.D.
Boston University, 2009, M.P.H., Social Behavioral Sciences/Health Policy and Management
University of Florida, 2006, B.S., Integrative Biology